Viewing data from:

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

ANDA

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN | A209692 | AMNEAL PHARMACEUTICALS OF NEW YORK LLC

2 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 9 NDCs

Highest NADAC/Unit

$0.5455

per ea

Lowest NADAC/Unit

$0.3895

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
83324013714QC MUCUS DM MAX ER 1200-60 MG	$0.5455	EA	Generic	—	2026-06-17
00536121388MUCUS RLF DM MAX ER 1200-60 MG	$0.5455	EA	Generic	—	2026-06-17
70677104901FT MUCUS DM MAX ER 1200-60 MG	$0.5455	EA	Generic	—	2026-06-17
70000046401MUCUS RLF DM MAX ER 1200-60 MG	$0.5455	EA	Generic	—	2026-06-17
70000046402MUCUS RLF DM MAX ER 1200-60 MG	$0.5455	EA	Generic	—	2026-06-17
70677105001FT MUCUS DM ER 600-30 MG TAB	$0.3895	EA	Generic	—	2026-06-17

Showing 6 of 9 NDCs.

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 1 NDC (1 FSS)

Lowest Price

$13.06

Highest Price

$13.06

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
00536-1161-37DEXTROMETHORPHAN 30MG/GUAIFENESIN 600MG	$13.06	FSS	The Harvard Drug Group L.L.C. dba Major Pharmaceuticals and Rugby Labs	05/31/2030

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

API Supply Chain0 active DMFs1 inactive

0 active API suppliers hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

DR REDDYS LABORATORIES LTDInactiveDEXTROMETHORPHAN, USP

DMF 155612001

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — 30MG;600MG

0 patents0 exclusivities▴

TABLET, EXTENDED RELEASE;ORAL | Approved: Nov 1, 2018

No patent or exclusivity listings for this strength.

#002 — 60MG;1.2GM

0 patents0 exclusivities▾

TABLET, EXTENDED RELEASE;ORAL | Approved: Nov 1, 2018